At the University of South Florida (USF), the fastest rising university in the U.S. News & World Report’s U.S. rankings, maintaining the pace of global engagement, high-impact research and innovation is supported with a metrics dashboard that informs strategic planning and provides ongoing insight into the university’s international activity.

The University of South Florida defines itself as a ‘global’ university and has the research metrics to back it up: in 2021, 60% of all USF citations involved an international collaborator. To support the continuation of high-impact, global research USF World – the USF unit that leads globalization efforts for students, faculty and alumni – set ambitious goals aligned to the university’s strategic plan. Among the goals is “To conduct high-impact research and innovation to advance frontiers of knowledge, solve global problems and improve lives.”

Defining global engagement with data

Laurel Thomas, International Research & Global Engagement Data Manager at USF World, supports the unit and university goal by providing access to international research data. As the data expert, Thomas needed to build a bridge between the USF moniker “global” and the data that illustrates USF’s global engagement. To address this gap Thomas led a data discovery project.

While every institution is unique, the process Thomas used can be replicated at other universities trying to understand their own research landscape:

• Know your department’s role and needs.
• Identify the data available and the data you need to find.
• Determine where your resources are, including people, software and subscriptions.
• Plan how to bring the data together.

The team at USF World had data about the international activities of students, partners and Fulbright Scholars but little visibility into faculty activity.

Gaining insight into faculty activity

Collaborating with Clarivate, Thomas brought in the important insights and analytics about faculty activity needed to present a comprehensive picture of international research activity and impact. Bibliometric data from Web of Science served as a proxy for faculty research data. Adding InCites provided better metrics and benchmarking against peers.

After the data sources were identified Thomas brought them together into a centralized database.

Today the USF Global Discovery Hub uses the data for dashboards with visualizations on faculty engagement worldwide, global student mobility, international partnerships and more. The Global Discovery Hub informs strategic planning and, importantly, highlights the faculty and researchers making a difference. Now Thomas has a tool to illustrate the impact of international research collaboration which she showcases in an annual report.

Thomas shared advice to help other institutions successfully undertake a similar project:

• Get the word out and share the benefits of a centralized database through collaboration with units across the institution.
• Run and save reports for frequently requested data and insights.
• Maintain easy access to insightful reports. They are key to gaining and maintaining support for the database.

A centralized database and dashboard support planning and funding allocations. With reporting on hand, units can engage in cooperative, strategic decision-making based on the latest data. Reports uncover new areas for partnership, how a program contributes to the metrics and more.

How we help

The bibliometrics from InCites and Web of Science are an integral part of the Global Discovery Hub and allow Thomas and the USF World team to understand the position of the university in relation to global research activity, identify new research opportunities and reveal the positive impact of global researcher engagement.

Partner with Clarivate analytics solutions and expert teams at your institution to:

• detect emerging trends,
• collect researcher activity data at scale,
• select the right indicators for benchmarking and evaluation,
• collate evidence of the broader, real-world outcomes of research.

Read the full case study and watch the webinar to learn more about how Laurel Thomas used Web of Science and InCites to identify, evaluate and benchmark key insights for successful international collaborations.

The post How to take an evidence-based approach to building a scholarly community appeared first on Clarivate.

The study was conducted collaboratively by Clarivate Senior Science Editor Shyama Ghosh, Senior Epidemiologist Shilpa Thakur, Managing Editor Stephen DuPraw and Senior Director Evelyn Davila.

LHON prevalence rates globally

Leber hereditary optic neuropathy (LHON) is a rare, maternally transmitted mitochondrial disorder that predominantly affects men in their teens and twenties and causes blindness. Degeneration of the retinal ganglion cells causes rapidly progressing vision loss, leading to permanent (non-painful) blindness within a year.

The Incidence and Prevalence Database (IPD) , a Cortellis solution, provides information on LHON prevalence and primary mutations, morbidity and mortality rates. Studies show a global LHON prevalence rate of 4.3 per 100,000, with Europe reporting a rate of 2.3 per 100,000. Prevalence rates vary across individual countries and regions, with higher rates in northeast England (1:31,000)^[1], the Netherlands (1:39,000), Denmark (1:54,000) and Finland (1:48,000)^[2], while the United States has a reported rate of 1:50,000^[3]. In South India, a single study recorded a prevalence rate of 1:737^[4].

LHON mutation rate variability affects therapeutic efficacy

Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. Multiple research groups have successfully used human wild-type ND4 gene transfer as a means of preventing retinal ganglion cell degeneration in patients with LHON^[5]. However, mutation rates can vary between patient groups within the same region, which may affect the therapeutic efficacy across patients.

The ND4, ND6 and ND1 mutations are responsible for 80%-90% of LHON cases and are commonly seen in familial cases. Globally, ND4 is the most common mutation, followed by ND6 and ND1. The REALITY study conducted in the United States, France, Italy, Spain and the United Kingdom in 2021 reported a distribution of ND4 (61%), ND6 (20%) and ND1 (18%)^[6]. Other studies have reported different percentages, with ND4 being the most prevalent mutation. In one study from Northern Ireland, the ND4 mutation had a 100% prevalence rate^[7].

A notable aspect of LHON is that only approximately 50% of men and 10% of women carrying one of the three primary mutations experience optic neuropathy. The timing of initial visual loss may not be significantly influenced by mutational status, but the patient’s genetic makeup can affect spontaneous visual recovery, which can occur many years after disease onset. Patients with the ND6 mutation tend to have a less severe disease progression, while those with the ND4 and ND1 mutations have a worse prognosis and a lower chance of spontaneous recovery.

Using real world data to analyze LHON dynamics

To better understand the dynamics of LHON, including disease prevalence and drug usage in the United States, we analyzed real world data from electronic health records (EHR), claims and pharmacy data from healthcare institutions and providers. The Clarivate U.S. real world data set covers 90% of the insured population in all U.S. states. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 and 377.16 annually in the claims dataset for the period of 2018-2021. Once LHON patients were identified, we mapped them to EHR data to analyze racial and ethnic differences.

Our real world data analysis showed a 1.3-fold increase in LHON prevalence per 100,000, with a higher diagnosed prevalence in males and non-Hispanic white people (as shown in Figures 1 & 2). Although non-Hispanic white people made up approximately 85% of all LHON patients, Clarivate EHR data indicates lower representation among Black/African American patients (11%), other races (3%) and Hispanic (1%) ethnicities.

Figure 1. LHON prevalence trends in the U.S.

Source: Clarivate real world claims data

Figure 2. Higher diagnosed LHON prevalence in men

Source: Clarivate real world claims data

We analyzed LHON treatment patterns using pharmacy and procedure claim records identified through NDC codes, CPT, HCPCS, ICD-9 and ICD-10 procedure codes. Our analysis included prescription trends for antibiotics, steroids, vitamins and ophthalmic-intraocular pressure reducing agents (prostaglandin analogs and alpha-adrenergic agonists) from 2018 to 2021. Our RWD analysis revealed that the majority of LHON patients received antibiotics (such as amoxicillin, azithromycin, ciprofloxacin and others) alone or in combination, as well as an increased number of vitamin prescriptions (including vitamins B, C, D and others) as part of their treatment (as shown in Figure 3).

Figure 3. Drug-treatment proportion of LHON in the United States

Source: Clarivate real world claims data product

An important step in treatment and market access pathways

Both published data and our real world data analyses provide consistent information on LHON prevalence and risk. Both datasets conclude that age and gender can predict visual failure, but predicting disease onset in LHON carriers remains a challenge.

There are some promising experimental treatments in pipelines, but successful commercialization will demand an in-depth understanding of this patient population and the current diagnostic and treatment pathways^[5].

The collection of real world data has become a critical pillar in the field of rare diseases, which are often characterized by scarcity and heterogeneity of data that are dispersed across countries^[8]. In recent years, we’ve seen an increase in awareness among healthcare providers and better diagnosis of rare diseases, leading to improved access to care for patients with these uncommon conditions.

Learn more about the Clarivate real world data offering here.

References

^[1]Sundaramurthy S et al. “Leber Hereditary Optic Neuropathy-New Insights and Old Challenges.” Graefe’s Archive for Clinical and Experimental Ophthalmology; V.259; No.9; 9/2021; p2461; DOI:10.1007/s00417-020-04993-1

^[2]Ueda K et al. “Nationwide Epidemiological Survey of Leber Hereditary Optic Neuropathy in Japan.” Journal of Epidemiology; V.27; No.9; 9/2017; p447; DOI:10.1016/j.je.2017.02.001

^[3]Filatov A et al. “Leber Hereditary Optic Neuropathy: Case Report and Literature Review.” Cureus; V.12; No.4; 4/20/2020; DOI:10.7759/cureus.7745

^[4]Gowri P et al. “A Hospital-Based Five-Year Prospective Study on the Prevalence of Leber’s Hereditary Optic Neuropathy with Genetic Confirmation.” Molecular Vision; 12/28/2020; p789

^[5]Sahel J et al. “Gene Therapies for the Treatment of Leber hereditary Optic Neuropathy.” International Ophthalmology Clinics; V.61; No.4; 10/2021; p195; DOI: 10.1097/IIO.0000000000000364

^[6]Yu-Wai-Man P et al. “Natural History of Patients with Leber Hereditary Optic Neuropathy-Results from the REALITY Study.” Eye; 4/28/2021; DOI:10.1038/s41433-021-01535-9

^[7]Poincenot L et al. “Demographics of a Large International Population of Patients Affected by Leber’s Hereditary Optic Neuropathy.” Ophthalmology; V.127; No.5; 5/2020; p679; DOI: 10.1016/j.ophtha.2019.11.014

^[8]Giannuzzi V et al. “Editorial: The Use of Real World Data for Regulatory Purposes in the Rare Diseases Setting.” Frontiers in Pharmacology; 13:1089033; DOI: 10.3389/fphar.2022.1089033

The post Understanding a rare disease through the lens of real world and prevalence data appeared first on Clarivate.

Our Top 100 Global Innovators report and list for 2023 is out. For 12 years, Clarivate has identified the companies and institutions whose research and innovation don’t just sit on the edge of possibility but define it. The Top 100 Global Innovators demonstrate the talent and judgement to lead, to create new possibilities and horizons. View this year’s most innovative organizations and explore the modern innovation landscape in our latest report.

Innovating at the edge of possibility

Improvement and innovation are achieved by those who go first, and often, those that go further than others and take greater risks. They do so in the knowledge that innovative new ideas and solutions to current problems influence more than their financials – they foster genuine improvement to the human condition and the health of our habitats.

Our annual Top 100 report identifies the 100 companies and organizations that demonstrate consistent above-the-bar innovation performance. These are organizations that choose to employ thousands of researchers, to invest in science and engineering, to pursue ideas that create new ground and to practice the leadership that means mountains are conquered.

But the path of the decision makers is getting tougher. They face pressure from all directions – from their customers, peers and within their own organizations. They balance competing priorities – of what is possible and what is most likely to deliver the greatest benefits and returns. The hazards of delay, failure and repetition weigh on the shoulders of the decision makers. Despite all of these challenges, the 100 most innovative organizations for 2023 demonstrate the talent and judgement to make tough innovation calls.

Introducing, the Top 100 Global Innovators 2023.

“It’s a great honor to be recognized as a Top 100 Global Innovator for the 10th consecutive year, along with so many esteemed companies. And we are excited about the future and the potential of innovation to help solve the world’s most pressing issues.”

Top 100 Global Innovators methodology – where all ideas compete equally

Our Top 100 Global Innovators program uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power.

To move from the individual idea strength to identifying the organizations that create them more consistently and frequently, we set threshold criteria that potential candidates must meet and then add a measure of their patented innovation output over the last five years^[1].

We do this by using our Derwent World Patents Index (DWPI), created by Clarivate science and engineering expert editors, which acts as the library of human invention and patented problem solving and the Derwent Patents Citation Index which focuses on inventions that have been referenced by applicants and patent examiners in later, downstream patent applications.

The Top 100 Global Innovators are those that sit at the very top of the candidate longlist, with the most consistently above-the-bar performance versus all other inventions in history.

You can learn more about our full methodology here.

New this year: the top 50 most cited institutions by the Top 100

The flow of modern innovation is fed by many intersecting pockets of research discipline. At Clarivate, by bringing together our enriched data on inventive activity and scientific discovery, we have the privilege of witnessing this flow, visualizing it and helping to open it up for the decision makers and innovators that lean on ideation data.

This year, for the first time, we track how knowledge created graduates to practical engineered solutions and identify the 50 institutions most often cited by the Top 100 Global Innovators 2023, a list that is diverse and global.

View the full list of 50 institutions here.

2023 report key findings

The Top 100 Global Innovators 2023 come from 12 countries and regions. Asia extends its dominance with 58 organizations on the list, up from 54 last year. From a sector perspective, ‘electronics and computing equipment’ is the largest industry sector of the Top 100 Global Innovators 2023. The ‘chemicals and materials’ sector and ‘semiconductor’ category are in joint second followed by the ‘automotive’ sector.

See more analysis from the 2023 report here.

Enriched data and intelligence beyond the Top 100

In this year’s report, we continue to extend the view  beyond  the Top 100 Global Innovators to better understand the global innovation ecosystem.

Leaning on our complete Global Innovators dataset, including the top 2,000 organizations longlisted in the process, we can visualize the performance of countries, regions and industry sectors.

This allows a deeper view into each industry, highlighting which countries and regions are taking the lead in key sectors, offering transformative intelligence to help companies and organizations navigate the innovation landscape and guide their innovation and intellectual property (IP) decision making.

Yet beyond the process of the Top 100 Global Innovators, complete global research and innovation datasets from Clarivate are used daily by innovators to visualize and guide their work and decision making, adding clarity to the complex dynamics of modern innovation ecosystems.

To learn more about obtaining our Complete Global Innovators dataset and the ways we can help you to achieve the potential of your IP, contact us here.

Gaining clarity from a complex global innovation landscape

The modern innovation landscape is a rich tapestry of individual threads that define the current boundaries of knowledge. Innovation and idea intelligence defining the current edge of possibility exists and is fundamental to innovation decision making.

We congratulate the Top 100 Global Innovators 2023. They continue to keep their eyes on the horizon and through their innovation, define the technological improvements of the decades to come.

Learn about the full Top 100 list, our methodology, the 2023 analysis and more here.

^[1] The five-year evaluation window for Top 100 Global Innovators 2023 is 2017 to 2021.

The post Top 100 Global Innovators for 2023 revealed [Report] appeared first on Clarivate.

In the report Demystifying the 5G standard essential patent landscape with manual SEP (Phase 2) published in October 2021, we presented findings from our extensive review of the granted patent families declared essential to 5G as of March 31, 2021. In this latest report, we present updated analysis of patents declared as essential to 5G as of December 31, 2021.

For this report, our SEP experts used three strands of analysis, examining:

• New patent families that had at least one granted patent against the declared 5G standards between April 1, 2021 and December 31, 2021
• Findings from the Phase 2 report
• Non-core patent families from the Phase 2 report for which new standards were declared from April 1, 2021

Key observations include:

• Almost 22% of declared patent families had a significant overlap with the declared standards and are therefore ‘core’ to 5G standards.
• 35% increase in core 5G patent families in the nine months from April 1, 2021
• Nearly 88% of core patents are held by the top 14 companies: Huawei, Samsung, LG, Qualcomm, Nokia, Ericsson, ZTE, Sharp, NTT Docomo, China Academy of Telecommunications Technology, Oppo, Apple, Vivo and Xiaomi.

To learn more, download and read the full report here. 

[1] Clarivate was retained to prepare this report by Sidley Austin LLP on behalf of a client. This report reflects Clarivate work product and analysis.

The post Demystifying the 5G standard essential patent landscape with manual SEP analysis: Phase 3 appeared first on Clarivate.

After many months of planning, we are launching the Preprint Citation Index, a multidisciplinary collection of preprints from leading repositories that helps researchers stay current with the newest research while maintaining confidence in the resources they rely on.

With the launch of the Preprint Citation Index, we are making it even easier for researchers to include preprints in their existing research workflows. Users can now locate and link to preprints alongside traditional scholarly literature while working in their preferred search and discovery environment, bringing more visibility to preprints.

With the addition of the Preprint Citation Index, the Web of Science can be used as a single portal to search across journals, books, proceedings, datasets and now preprints – streamlining the research process and helping to make important connections faster.

Increasing focus on preprints

In academic publishing, a preprint is a version of a research paper or outcome that is publicly available in a repository before it has been peer reviewed. Preprints have been around since the early ’90s, but the COVID-19 pandemic increased the attention on them by highlighting the importance of shortened publication timelines as well as the challenges of using unreviewed sources throughout the research process.

For researchers focused on today’s urgent global challenges, access to preprints can significantly speed up scientific progress. We’ve created the Preprint Citation Index so researchers can discover and use both preprints and journal articles, on one trusted platform.

The Preprint Citation Index in action

The Preprint Citation Index currently provides nearly two million preprints from arXiv, bioRxiv, chemRxiv, medRxiv and Preprints.org. We plan to add preprints from a dozen additional repositories as well as display open peer reviews on Preprint Citation Index throughout 2023.

Our unique, multidisciplinary collection of preprints helps to:

• Locate versions of record (where applicable) for preprints: Find and reference peer-reviewed articles with links from preprints to Web of Science Core Collection records.
• Connect preprints to journal articles: Uncover connections between cutting-edge preprints indexed in the Preprint Citation Index and journal articles indexed in the Web of Science Core Collection via citation linking.
• Expand the view of a researcher’s expertise: Place preprints in the context of a researcher’s career with preprints displayed on an author’s Web of Science Researcher Profile.
• Monitor new research across several repositories: An author can set an alert for keywords or a named researcher of interest to be notified when relevant preprints become available.

Preprint Citation Index and the Web of Science Core Collection: separate but complementary

It’s important to note that the new Preprint Citation Index is a standalone database that provides researchers and graduate students with immediate access to an up-to-date, aggregated and searchable set of preprints linked to Researcher Profiles. Preprints are not included in the Web of Science Core Collection.

To help ensure this is clear within the Web of Science platform, when running an ‘All Databases’ search, the default setting is filtered to exclude preprints – meaning that you will need to ‘opt in’ to include them in your search. This feature can be toggled on and off and saved as a preference. When included in the search, preprints are clearly marked in the search results and full record page with a disclaimer.

Additionally, preprint citations are also not included in Times Cited counts, the Journal Impact Factor (JIF) or any other citation metrics within the Web of Science Core Collection or Journal Citation Reports. We are linking preprints and the scholarly articles they cite, so researchers can find the latest research relating to an article. This link does not display a numerical citation count. Under the Times Cited counts for an article, users can see a link to view citing preprints.

Impact of an integrated research publication ecosystem

We know that searching aggregated preprint content alongside other content sets saves valuable time – streamlining the research process and helping researchers make important connections faster.

We anticipate that discovering preprints in the Web of Science environment will also simplify the process of evaluating preprint quality and trustworthiness by connecting them to the versions of record and linking to other scholarly output from preprint authors.

This new database can also help researchers identify trends in the preprint landscape with the help of standardized metadata, including the ability to analyze preprint output from 2021 onwards by institutional affiliations, regions or funders.

We’re excited to see how researchers will use the Preprint Citation Index to support faster, higher quality research and how this might broaden and strengthen the global research ecosystem – opening doors to a more open, transparent and connected future.

For more information about the Preprint Citation Index, check out our website.

The post The Preprint Citation Index: linking preprints to the trusted Web of Science ecosystem appeared first on Clarivate.

As patent filings grow at unprecedented rates, companies are beginning to realize the strategic importance of patent renewals, unlocking their ‘data power’. A new report from Clarivate, Global patent renewals trends, leans on enriched patent and IP case data paired with human expertise and technology to analyze patent filing activity. Through the report, law firms and in-house legal teams can gain a better understanding of maintenance behaviors to help unleash annuities’ strategic value and optimize patent portfolios.

Annuities – more than meets the eye

Patents are important IP assets with deep commercial value. Beyond the initial filing and obtaining of a patent, the decision to renew or abandon a patent plays a significant strategic role, especially where patents are critical to business operations.

However, patent renewals are often seen as a primarily administrative or operational aspect of patent enforcement. When organizations view renewals as a mere formality in patent lifecycles, they inadvertently underplay the strategic value of patents.

In contrast, when organizations recognize annuities ‘data power’ they can capitalize on the possibilities of analyzing data derived from worldwide patent renewals and draw intelligence to inform their patent portfolio management.

In our latest special report, Global patent renewals trends, we explore how patent renewals can become strategic devices and act as decision-making points for organizations.

Key annuities trends

After two decades of global patent renewals, we have the technological tools to curate and analyze renewals data and take a global view of patent renewal trends. Through analyzing the life of 70 million patents across five key jurisdictions, our report aims to answer a simple question of what survives.

We focus on those patents remaining in portfolios, removing those that have explicitly lapsed due to the non-payment of fees as indicated in legal status information. By combining grant and abandonment rates, we can better understand the chances that a similar patent or application in each field would survive. In doing so, we can see potential renewal dynamics, helping patent holders make contextualized decisions about their exposure to opportunity risk.

Key findings from our report include:

• Sectors vary considerably in their abandonment rates: If we consider that even one percentile point can represent thousands of patents and millions of dollars, the sectors’ differences are vast — with the difference between the industry with the highest and lowest abandonment rate at 12%.
• Life science verticals have longer patent lifecycles: Life science verticals, including medical, biotechnology and pharmaceuticals, have the highest survival rate, with 35% of patents still in force after 20 years.
• Brand-centric sectors move ‘faster’: Brand-centric fields have some of the lowest patent renewal rates, with less than 25% of patents in the luxury, fashion and sports sectors still in force by year 20.
• Mainland Chinese filings continue to dominate the global landscape: Looking at the worldwide footprint of filings, Mainland China is overwhelmingly the jurisdiction of choice, with academic and government institutions being the biggest filers.

Transformative patent intelligence enables patent portfolio optimization

Clarivate has one of the most comprehensive IP solution portfolios on the market. By pairing enriched data with analytics and expertly curated insights, we can offer practitioners a more holistic understanding of the patent renewals landscape, giving them clarity to navigate the complex, to anticipate risk and leverage opportunities, optimizing their patent portfolios.

Read the new report: Global patent renewal trends: Unpicking what survives to understand maintenance behaviors better and unleash annuities’ strategic value.

The post Unlocking the promise of patent renewals appeared first on Clarivate.

In a new white paper from Clarivate,  Don’t let standards slip: How to prioritize your efforts when everything is essential, the European Telecommunications Standards Institute (ETSI) database showed that 36% of declared SEPs – 144,000 – were declared within the past two years. Increasingly, SEPs are spreading to industries including automotive, Internet of Things (IoT), healthcare and more.

Whether your company is a SEP owner or implements technologies using SEPs, you need to be aware of the current technological and legal landscape around SEPs.

What implementers need to know

If you are an in-house IP practitioner or in research and development (R&D) at one of the many companies now affected by SEPs, you likely know that ’essential’ patents designated by their owners may, in fact, not be essential to the implicated technology. As we note in our white paper, a 2016 European Commission report suggested that only between 10 to 50% of patents declared to be essential in the ETSI actually are.

In addition, for companies doing business across borders, the legal landscape differs among major markets. For example, in June 2022, the United States Department of Justice and U.S. Patent and Trademark Office, along with the National Institute of Standards and Technology (NIST) announced a new case-by-case approach to SEP enforcement. Although the change in policy was presented by the agencies as promoting innovation and competition, it may lead to increased uncertainty and litigation around SEPs.

The ambiguities around designation of SEPs and a patchwork of national laws and policies regarding enforcement and the meaning of fair, reasonable and non-discriminatory (FRAND) licensing terms have complicated the process of compliance for a variety of companies. For SEP implementers – particularly those in industries that are only beginning to develop standards – this uncertainty draws attention and resources away from higher volume and more straightforward development and patent work.

What SEP owners need to know

As with implementers of SEP-based technologies, SEP owners are dealing with emerging technologies and industries. As opportunities for FRAND licensing expand, current and potential SEP owners also face growing complexities in declaring SEPs and evaluating portfolios of non-declared patents for applicability to developing standards.

For R&D and IP teams, investment throughout the pipeline often requires specific and comprehensive market intelligence that might not seem like a priority for your team right now.

Evaluating the SEP landscape, re-evaluating your SEP strategy

It is key for both owners and implementers to position themselves to take advantage of new standards, prepare for FRAND licensing requests and mitigate risks from competitors. This might involve re-evaluating your SEP strategy – and perhaps even your entire IP strategy which can include everything from educating company stakeholders to evaluating competitors and potential collaborators.

Understanding the SEP environment, by partnering with experts with deep knowledge and experience in SEP projects for essentiality analysis, market intelligence or litigation intelligence, can help organizations gain clarity from the complex and better understand SEP opportunities and challenges.

Connect with Clarivate

To learn more about the current SEP landscape and how to prepare your business for the future, download our new white paper, Don’t let standards slip: How to prioritize your efforts when everything is essential.

Connect with one of our SEP experts to discuss how we can help your team navigate SEP challenges thoroughly and efficiently.

Authors

Dinesh Narayanan Kutty
Senior Director, Product Management
Clarivate

Gaurav Sawant
Associate Director, Service Operations
Clarivate

The post How your IP and R&D teams can strategize and prioritize for the evolution of SEPs appeared first on Clarivate.

Patent filings with biological sequences, i.e. nucleotide or amino acid sequences, often have a Sequence Listing File prepared by the patentees for national patent offices. This Sequence Listing File presents the biological sequence data in a standardized format.

However, the Sequence Listing is not required and many patent filings for biological sequences do not include this additional documentation. As a result, a significant portion of biosequence patents become difficult to retrieve using conventional patent search tools.

To understand how many biosequence patents are filed on average without a Sequence Listing, Clarivate analysts reviewed more than 34,500 patent applications to the United States Patent and Trademark Office (USPTO), China National IP Administration (CNIPA) and the World IP Office. Based on this review, an estimated 18% of biosequence patent applications in 2021 were submitted to these patent offices without a Sequence Listing.

Figure 1: Estimated percentage of 2021 patent filings by jurisdiction where the Sequence Listing was not provided by the patentee)

Source: GENESEQ

While the percentage of patent applications filed without a Sequence Listing has been decreasing over time for the three jurisdictions studied, the proportion is still significant, particularly for patents filed with the CNIPA. The biggest decrease in patent filings without a sequence was observed for World IP Office (WIPO) applications—down from 29% in 2017 and 28% in 2019.

To help researchers bridge this information gap, Clarivate has developed the GENESEQ database. Using a proprietary process that incorporates machine learning and human review, our team identifies and indexes all sequences found in biosequence patent filings, regardless of whether a Sequence Listing is available.

By indexing both the sequences presented in the Sequence Listing and the sequences disclosed in patent filings, GENESEQ provides a more comprehensive view of the biological sequence patent landscape. This allows researchers to more accurately assess the novelty of a new sequence and capture a complete picture of the patent landscape surrounding specific sequences.

To find out more about the GENESEQ database and related IP solutions that can help you make data-driven decisions with speed and confidence, contact us.

The post Finding patented biological sequences for patents without a Sequence Listing appeared first on Clarivate.

“We need more than funds from the federal government, we need strategic focus,” said Shirley Ann Jackson, the President of Rensselaer Polytechnic Institute earlier this year in a North American University President’s forum on the Evolving Role of Universities in the American Innovation System. And in August, the CHIPS Act delivered exactly the sort of scientific challenge that can provide the focus that had been lacking in America. Formally known as the ’Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022,’ the CHIPS Act received unheard of bipartisan support, passing through both the U.S. House and Senate, with the Senate voting 64-33 for passage.

The CHIPS Act is a straightforward combination of national security and economic policy that Americans are finding easy to rally behind. The bill formalizes a large federal investment in semiconductor manufacturing and research and development to boost U.S. competitiveness, innovation and national security.

An American science policy with impact

CHIPS Act represents a national science policy with concrete objectives and the funding, strategy and planning to lead to success. Just as the end of World War II and the launch of Sputnik created a sense of purpose for U.S. science policy, here we have a similar level of commitment and purpose – a real and urgent national goal tied to the investment of billions across multiple years to address it. The US government is investing to create a domestic supply-chain for semiconductors and electronics after having witnessed the havoc wrought on the US economy due to the supply chain disruptions during the Covid-19 pandemic. (See Figure 1)

In this case, the American government is working to create innovative and secure chip research and manufacturing capacity within its borders. The CHIPS Act uses federal dollars as a catalyst to encourage R&D and translational work, tapping into the combined expertise of universities, industry partners and states working collaboratively to produce innovation and chip manufacturing capacity.

FIGURE 1 – The problem in brief – The global economic problems caused by the COVID-19 pandemic showed the economic and security vulnerabilities posed by supply chain disruptions.

Source: The CHIPS and Science Act: Here’s what’s in it. McKinsey and Company, Oct 4, 2022;

Turning pronouncements into actions

According to a report from McKinsey & Company, there are specific provisions for allocating the investment of $280B over the next ten years, including four principal mechanisms to channel funds to U.S. academic institutions.

1. $11B for academic research – The National Science Foundation (NSF) will oversee the distribution of $11B in new grants to be distributed over the next five years through a newly created National Semiconductor Technology Center.
   • The President’s Council of Science and Technology Advisors recommends these funds be concentrated in six ’Coalitions of Excellence’ that are meant to be innovation/collaboration hubs with industry and regional development.
2. $14B for basic scientific research – The Department of Energy (DOE) will be allocated an additional $13B across the next 5 years – $2.5B/year for investment into ’basic science’. This will swell the existing DOE research budget to $50B. In addition, there is an additional $1B to be invested in research for low-energy/low-carbon emission steel production.
3. $10B for research/infrastructure in 20 regional hubs – The Department of Commerce will be allocated $10B across the next five years to invest in the creation and development of Regional Manufacturing Clusters with these funds being overseen by the National Institute of Science and Technology (NIST).
4. $200M to create a national microelectronics training network overseen by the Commerce Department in coordination with NSF. This is meant to support “at least 50 ‘hub’ universities and colleges geographically distributed across the country, including minority-serving institutions .”

What does this mean for the American academic research enterprise?

The opportunity for U.S. research universities is historic – the CHIPS Act will boost federal research funding by more than 15% per year, adding roughly $7B/year to a budget of as much as $46B. For university research leadership, the expansion of funding across the agencies opens up questions of focus and institutional objectives. With multiple paths available, where should we compete?

As American universities compete to participate in these initiatives, the first step to developing a CHIPS Act strategy is to complete a realistic assessment of a university’s research strengths and weaknesses. Resources and energy should be concentrated on those areas in which an institution is most likely to win. To help with that winnowing process, the early movers are asking the following questions as part of their campus-wide strategic planning:

• Are we best suited to simply apply for the new basic science grants – biology, chemistry, physics, astronomy – through the expansion of DOE funding?
• Should we lead (or join) a coalition looking to wins a regional manufacturing cluster from the Department of Commerce?
• Are we eligible for the NSF funds focused on innovation in semiconductor research and development?

Of course, budget authorization is not the same as actual funding appropriation. However, some dollars have already been allocated and the bi-partisan nature of the bill implies that funding is more likely than less. As such, the scale of the funding here demands that university executives evaluate and choose a plan of action that can be implemented as soon as funding is approved.

“I think the investments we make should be directed to the areas that have a critical bolus of top-notch science, in a particular area that we can build on.”

Regardless of the specific rules that will be written, the most important and critical factor in winning some of this research funding is the strength of the underlying science taking place in university labs.

Although there is not yet clarity as to the evaluative rubric that will be used for the various programs in the CHIPS Act, the meetings of the President’s Council of Advisors on Science and Technology (PCAST) have shed light on the metrics most likely to be used to judge grant applications. In answer to a question “How will you assess what is a good investment?” U.S. Secretary of Commerce Gina Raimondo answered, “First, the quantity and quality of intellectual capital in a region; second, the quantity and quality of research.”

As with all institutional initiatives, a formal strategic plan that begins with assessment, includes goal setting, resource allocation and careful monitoring of progress should be created. To help determine a university’s best plan of action, take the following steps:

Step 1 – Complete a research portfolio disciplinary assessment. Create a full accounting of your institution’s publication record on a discipline-by-discipline basis. By evaluating both the quantity and the quality of the underlying science, it is possible to map an institution’s investigative strengths.

Step 2- Map the university’s strengths/deficits relative to each of National Science Foundation and Department of Energy criteria (as currently understood). Each of the funding appropriations are trying to achieve slightly different objectives, while they all fit under the broad heading of Semiconductor Manufacturing and Innovation – the purpose of every part of the bill . To determine if a school has a better chance of being part of the Innovation Hubs or simply applying for DOE grants, school leaders should do a high-level fitness analysis, measuring things like:

• Geographic – is the institution located in a favorable zone from an economic development perspective?
• Disciplinary/Thematic ‘fit’ within overall map of R&D within semiconductors: How and why does what we do at X University contribute to the overall project?
• Measures of scale/commitment – Volume and recency of publications shows the volume of R&D activity and work on campus
• Innovation hubs – What other attributes of a hub exist? Companies? State funding? Tax incentives?
• Curricular review to determine fit with “National Microelectronics Training Network;” Industry liaison to serve as network connection accelerator

Step 3 – Create a tactical project plan to address highest probability opportunities. To be considered as part of an innovation hub, the institution needs to partner with other universities, companies and state/local leaders. Create the operational working groups and teams, with governance and oversight, to ensure success:

• Find partners/consortium to lead/join
• Identify net new grant opportunities in disciplinary areas of focus, creating mechanisms to push information outward and coordinate responses internally
• Create project plan, marketing pitch, advancement campaigns

The CHIPS Act provides an opportunity for institutions to dramatically expand their research standing. As with most things, success will come to those who are most prepared and focused in their efforts.

Clarivate^TM can help you and your teams chart a path forward. Contact us to discuss the CHIPS Act and how Clarivate can help.

References:

The CHIPS and Science Act: Here’s what’s in it. McKinsey and Company, Oct 4, 2022;
The Evolving Role of Universities in the American Innovation Ecosystem. University Presidents Forum – hosted by Duke University March 3, 2022: https://www.youtube.com/watch?v=9GgEI6j9K_c&list=WL&index=21&t=3750s;
Advancing the US Innovation Ecosystem & Innovation Hubs: Implementation of the CHIPS & Science Act. President’s Council of Advisors on Science and Technology – Sept 21, 2022 https://www.whitehouse.gov/pcast/meetings/2022-meetings/
“Regional Innovation Provisions in the CHIPS and Science Act” Tim Clancy, American Institute of Physics, October 26, 2022: FYI: Science Policy (online newletter)

The post What American university research leaders need to know to participate in the CHIPS Act appeared first on Clarivate.

The annual Drugs to Watch report from Clarivate spotlights late-stage pre-launch drugs and biologics set to become blockbusters within five years of market authorization and/or transform treatment paradigms. See who made this year’s list.

We are now seeing personalized medicines representing a significant cohort in new drug approvals. These treatments represent a substantial leap forward for life sciences, in many cases providing treatments for previously untreatable diseases. However, because they are highly targeted, they address smaller potential patient cohorts than the mass-market treatments of yore, forcing pharmas to thread the needle on pricing in order to recoup the costs of development and fund the next cycle of innovation. In some instances, the resulting pricing may prompt payors to place tight constraints on novel therapeutics, limiting both their commercial potential and their potential benefits to patients. Even the most successful new targeted therapeutics now routinely fall short of blockbuster status, which was, in past years, the principal measure of our Drugs to Watch picks.

An updated methodology

With this evolving dynamic in mind, we have revised our Drugs to Watch methodology to include not just drugs forecast to earn more than $1 billion in annual global revenue five years after launch, but also drugs with critical potential clinical impact – those that answer unmet patient need and advance the standard of care significantly. For this year’s Drugs to Watch report, we drew from the expertise of more than 160 Clarivate analysts covering hundreds of diseases, drugs and markets and tapped 11 integrated data sets that span the R&D and commercialization lifecycle to identify 15 Drugs to Watch, including:

• Bimekizumab (BIMZELX®)
• Capivasertib
• Daprodustat (Duvroq)
• Deucravacitinib (SOTYKTU)
• Foscarbidopa/foslevodopa
• Lecanemab (LEQEMBI) and donanemab
• Lenacapavir (Sunlenca®)
• Mirikizumab
• Pegcetacoplan (EMPAVELI®/ASPAVELI®)
• Ritlecitinib
• Sparsentan
• Teclistamab (TECVAYLI®)
• Teplizumab
• Valoctocogene roxaparvovec (ROCTAVIAN)

Key trends

In addition to the growing cohort of personalized medicines, the report touches on several other trends of importance to the biopharma industry in 2023, namely:

• the rapidly growing marketplace for biopharmas in Mainland China, where regulatory reforms have greatly expanded access to treatments and
• the need to balance development of complex biologics that address diseases of concern in the wealthy world, such as the recent burst of innovation in cancer and autoimmune disorder therapeutics, with development of new medicines for global scourges outlined in the United Nations Sustainable Development Goals, including diseases like tuberculosis, malaria and waterborne illnesses.

The urgency of transformative innovation

R&D productivity remains a challenge for pharma in 2022, with a decline in NMEs approved across the globe. This may reflect a COVID-era pivot by companies toward seeking solutions to the disease, as well as the impact of the pandemic on clinical trials and regulator visits due to travel restrictions, etc. These ephemeral factors aside, R&D is getting more difficult, with more complex medicines and emerging but as-yet experimental platforms in play.

Robust data sets, properly used and harmonized, provide an opportunity to accelerate innovation – but in order to realize their potential, companies must be able to combine data sets from disparate sources and coax actionable insights from them. At Clarivate, we work alongside industry leaders to help them navigate the ocean of data and speed much-needed treatments to market in order to help patients live better, longer lives.

You can find the Drugs to Watch 2023 report, along with a host of other resources, here.

The post The Drugs to Watch in 2023 appeared first on Clarivate.